Alfred Health
The normal human immune system functions not only to remove infected cells but also to remove damaged or pre-cancerous cells.
Cancer cells are able to evade removal by acquiring mutations that result in increased survival, even in the presence of cues that would normally result in their removal.
Our laboratory is identifying pathways that can be targeted therapeutically to bypass the survival signal in cancer cells and promote their clearance. We have already shown that deleting kinases that are normally activated by lnterleukin-3 promotes clearance of AML.
Find out more about the Leukaemia Signalling Pathways Group
Researchers are a step closer to offering older patients with an aggressive blood cancer, acute myeloid leukaemia (AML), a new less-toxic treatment option.
The Alfred and Monash University are set to establish Australia’s first dedicated blood cancer research centre, thanks to a $1.2 million grant from the Australian Cancer Research Foundation (ACRF).